Dr. Hutton Chapman, Assistant Professor of Pediatrics and inaugural recipient of the Dr. G. Ralph Corey Legacy Award, has published findings from his sponsored project. The new study published in Pediatric Blood & Cancer highlights a successful framework for introducing high-dose methotrexate (HD-MTX) to treat pediatric mature B-cell non-Hodgkin lymphoma in resource-limited settings.While HD-MTX is highly effective, its potential for severe toxicity often limits its use in low- and middle-income countries.
To overcome these barriers, researchers at the Bugando Medical Centre in Mwanza, Tanzania, utilized Active Implementation Frameworks to map resources, engage stakeholders, and build novel educational and decision-support tools. Following the protocol’s launch, 10 pediatric patients safely received a cumulative 27 cycles of HD-MTX with minimal protocol deviations and only one reported major adverse event. The study demonstrates that implementation science can provide a scalable, generalizable pathway to safely deliver complex cancer therapies in low-resource environments.
Read more here.